Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Some Adverse Events For Generics Still Should Not Be Submitted Through eCTD Portal, US FDA Says

Executive Summary

Implementation of eCTD regulations for commercial INDs did not change system for submitting premarket bioavailability/bioequivalence study reports intended to support ANDA approval, agency clarifies.

You may also be interested in...



New CDER No. 2 May Impact FDA's Safety Monitoring Aspirations

Patrizia Cavazzoni, CDER's new deputy director for operations, has safety surveillance background and wants to see FDA continue to grow its capabilities.

Clinical Study Disclosures Will Make Drug Reviews More Efficient – Gottlieb

US FDA pilot program linking drug approval documents to sponsors' clinical study reports will improve review efficiency and access to information by medical researchers and drug developers, commissioner says; move also could aid sponsors when it comes to reimbursement decision-making, Foley and Lardner's Rosen predicts.

Previous EU Guidance Wrong On Format Rule For Mutual Recognition Procedures

Contrary to previous guidance, applicants must submit as of Jan 1 all MRP submissions in eCTD format, including submissions for ongoing regulatory activities which may not have been originally submitted in this format.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel